Biotron Limited (OTC:BITRF) Filings

Biotron Limited

Filings

FilingDateTypeFiled with
Executive Director CEO Commences - Appendix 3XNov 8, 2026Management or board changeASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 27, 2026Quarterly reportASX
Biotron Receives Additional $208,463 Tax RefundOct 22, 2026ResultsASX
Annual Report/Notice of AGM/Proxy FormOct 22, 2026Meeting noticeASX
Director Appointment Michael Thurn & Appendix 3XOct 18, 2026Management or board changeASX
Appointment of CEO and Executive DirectorOct 13, 2026Management or board changeASX
Resignation of Managing Director and Appendix 3ZSep 13, 2026Management or board changeASX
Change of Share RegistrySep 3, 2026Other filingsASX
Investor PresentationSep 2, 2026Other filingsASX
Appendix 4GAug 26, 2026Other filingsASX
Corporate Governance StatementAug 26, 2026Annual reportASX
Full Year Statutory Accounts and Appendix 4EAug 26, 2026Annual reportASX
Change in substantial holdingAug 17, 2026Ownership change noticeASX
HBV Treatment to Progress Towards Human TrialsAug 16, 2026Other filingsASX
Sedarex First Milestone MetJul 12, 2026Other filingsASX
$525K R&D Rebate ReceivedJun 3, 2026ResultsASX
Hepatitis B Virus Program UpdateMar 17, 2026Other filingsASX
Half Yearly Report and AccountsFeb 26, 2026Interim reportASX
Successful Issue of the Entitlement Offer ShortfallJan 29, 2026FinancingASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 28, 2026Quarterly reportASX
Security Class Reinstatement to Quotation - BITODec 21, 2025Trading halt or suspensionASX
Rights Issue CloseDec 19, 2025FinancingASX
Security Class Suspension from Quotation - BITODec 14, 2025Trading halt or suspensionASX
Non-Renounceable rights Issue ProspectusNov 18, 2025Offer documentASX
Acquisition of Sedarex Limited and $2.5m capital raisingOct 15, 2025Acquisition or disposalASX
Trading HaltOct 12, 2025Trading halt or suspensionASX
Pause in TradingOct 12, 2025Trading halt or suspensionASX
Full Year Statutory Accounts and Appendix 4EAug 27, 2025Annual reportASX
Rights Issue ClosedApr 7, 2025FinancingASX
Replacement ProspectusMar 12, 2025Offer documentASX
Response to ASX Query LetterMar 12, 2025Explanation requestASX
Supplementary ProspectusMar 4, 2025Offer documentASX
Response to ASX Aware QueryMar 3, 2025Explanation requestASX
ProspectusMar 2, 2025Offer documentASX
Renounceable Rights IssueFeb 27, 2025FinancingASX
Updated Appendix 4CFeb 3, 2025Quarterly reportASX
Agreement with C14 Consulting GroupNov 26, 2024Other filingsASX
$1.8M R&D Rebate ReceivedOct 13, 2024Other filingsASX
BIT225-012 PHASE 2 COVID-19 CLINICAL TRIALSep 5, 2024Other filingsASX
BIT225 Phase 2 HIV Efficacy Trial Meets Primary ObjectivesJun 19, 2024Other filingsASX
POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIVApr 4, 2024Other filingsASX
Response to ASX Price QueryMar 26, 2024Explanation requestASX
COMPLETION OF PHASE 2 COVID CLINICAL TRIALAug 16, 2023Other filingsASX
Second Site Approved for Phase 2 Covid-19 TrialMay 12, 2023Other filingsASX
Commencement Phase 2 Covid-19 Clinical TrialMay 3, 2023Other filingsASX
Completion of Phase 2 HIV-1 Clinical TrialsMar 8, 2023Other filingsASX
International Presentation of BIT225 COVID-19 DataFeb 20, 2023Other filingsASX
$1.43M R&D rebate receivedNov 18, 2022Other filingsASX
Commencement of Rights Trading - BITRCOct 31, 2022Other filingsASX
Renounceable IssueOct 26, 2022Other filingsASX
Second BIT225 Phase 2 HIV-1 Clinical Trial Fully RecruitedOct 3, 2022Other filingsASX
Bit225 Covid-19 Human Study CommencedSep 13, 2022Other filingsASX
BIT225 Phase 2 HIV-1 Clinical Trial Fully RecruitedAug 23, 2022Other filingsASX
POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAMMay 30, 2022GuidanceASX
BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALSMay 2, 2022Other filingsASX
Quarterly Cash Flow Report Appendix 4CApr 26, 2022Quarterly reportASX
Quarterly Activities ReportApr 26, 2022Quarterly reportASX
$1.56M R&D Rebate ReceivedApr 5, 2022Other filingsASX
BIT225 Effectiveness Against COVID-19 in AnimalsMar 17, 2022Other filingsASX
Quarterly Appendix 4C Cash Flow ReportJan 27, 2022Quarterly reportASX
BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALSNov 24, 2021Other filingsASX
COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALSNov 1, 2021Other filingsASX
Quarterly Cash Flow ReportOct 27, 2021Quarterly reportASX
Full Year Statutory Accounts and Preliminary Final ReportAug 27, 2021Annual reportASX
$1.4M R&D Tax RebateApr 28, 2021Other filingsASX
Appendix 4C - quarterlyApr 28, 2021Quarterly reportASX
Quarterly Cashflow ReportJan 28, 2021Quarterly reportASX
Biotron Compounds Show Activity Against SARS-CoV-2 VirusSep 6, 2020Other filingsASX
Full Year Statutory AccountsAug 27, 2020Annual reportASX
BIT225 Reverses HIV-Induced Immune EvasionJul 6, 2020Other filingsASX
R&D Tax Refund ReceivedMar 18, 2020Other filingsASX
BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONSMar 11, 2020Other filingsASX
Biotron to Test its Compounds Against CoronavirusFeb 5, 2020Other filingsASX
Biotron Secures $5.1 Million Underwriting AgreementNov 8, 2019Other filingsASX
Presentation to InvestorsOct 31, 2019Other filingsASX
Appointment of International Advisory Board for BIT225Oct 1, 2019Other filingsASX
Presentation at BIO 2019Jun 7, 2019Other filingsASX
PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATANov 28, 2018Other filingsASX
Response to ASX aware letterOct 30, 2018Explanation requestASX
Biotron Secures $4.7 Million Underwriting AgreementOct 16, 2018Other filingsASX
$1.07 million R&D Tax Incentive ReceivedOct 14, 2018Other filingsASX
Significant Immunological Outcomes in BIT225 HIV-1 TrialSep 28, 2018Other filingsASX
Update on Progress of BIT225 Phase 2 HIV-1 Clinical TrialAug 7, 2018Other filingsASX
Response to ASX Appendix 4C QueryMay 10, 2018Explanation requestASX
Biotron Compounds Demonstrate Activity Against HBVNov 15, 2017Other filingsASX
$1.6 Million R&D Tax Incentive ReceivedNov 1, 2017Other filingsASX
BIT225 Phase 2 HIV-1 Clinical Trial UpdateJun 15, 2017Other filingsASX
$1.6 Million R&D Tax Rebate ReceivedFeb 12, 2017Other filingsASX
BIT225 Accelerates HIV-1 Virus ReductionFeb 6, 2017Other filingsASX
Zika Virus Program UpdateAug 22, 2016Other filingsASX
Biotron compounds demonstrate activity against Zika virusMay 23, 2016Other filingsASX
$1.5 Million R&D Tax RebateApr 20, 2016Other filingsASX
Trading haltMar 30, 2016Trading halt or suspensionASX
Phase 2 Hepatitis C Trial SuccessMar 17, 2016Other filingsASX
BIT225 MAY HAVE A BROADER ROLE IN LIMITING HIV-1 INFECTIONFeb 18, 2016Other filingsASX
BIOTRON COMPOUNDS TESTED FOR ACTIVITY AGAINST ZIKA VIRUSFeb 16, 2016Other filingsASX
INTERIM HCV GENOTYPE 3 DATA FROM BIT225-008 STUDYFeb 11, 2016Other filingsASX
Annual Report to ShareholdersFeb 10, 2016Annual reportASX